
    
      OBJECTIVES:

      Primary

        -  Determine the efficacy of sunitinib malate in patients with locally recurrent or
           metastatic papillary renal cell carcinoma.

      OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats
      every 6 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed at 28 days and every 2 months
      thereafter.
    
  